About CONSA
The Consortium on Newborn Screening in Africa, or "CONSA," is a collaboration between the American Society of Hematology (ASH) and hematologists and public health authorities across sub-Saharan Africa to demonstrate the effectiveness of newborn screening and early therapeutic interventions for babies with Sickle Cell Disease (SCD). Early identification via newborn screening followed by administration of antibiotics, antimalarial prophylaxis, and specific immunizations has been shown to dramatically reduce childhood mortality from SCD. The data collected from this effort will be used to define the burden of the disease, demonstrate the efficacy of screening and early intervention, and advocate for expanded services in these areas.
Next CONSA Meeting: December 6, 2024 (ASH AM in San Diego, California)
World Sickle Cell Day Video
Learn how CONSA is working to expand capacity for sickle cell disease screening, clinical care, and research in sub-Saharan Africa.
CONSA One-page Flyer (A4 size)
ASH 2022 CONSA AND AD Full no crop marks.pdfNewborn Screening
Despite progress made in reducing child mortality and improving health outcomes, many African countries do not have the capacity to diagnose and treat genetic disease, those passed from parents to children.
CONSA One-page Flyer (US Letter size)
ASH Africa NBS SCD Africa Flyer A4 2023 HIGHREZ.pdf